Limits...
Comparative serum proteomic analysis identified afamin as a downregulated protein in papillary thyroid carcinoma patients with non-131I-avid lung metastases.

Song HJ, Xue YL, Qiu ZL, Luo QY - Nucl Med Commun (2013)

Bottom Line: Differential protein analysis was performed using two-dimensional gel electrophoresis.Candidate protein spots showing differences in expression between the two groups were identified by means of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and were validated by western blotting.We found that afamin is downregulated in the serum of papillary thyroid carcinoma patients with non-131I-avid lung metastases.

View Article: PubMed Central - PubMed

Affiliation: Department of Nuclear Medicine, Shanghai Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai, China.

ABSTRACT

Background: The loss of 131I uptake ability in metastases from differentiated thyroid carcinoma (DTC) is becoming a major obstacle in radioiodine treatment. However, there is no effective way to screen for 131I uptake ability in metastases. The identification of differentially expressed proteins by serum proteomics may contribute to our understanding of the mechanisms underlying the dedifferentiation of DTC.

Materials and methods: Serum samples were obtained from papillary thyroid carcinoma patients with non-131I-avid lung metastases and 131I-avid lung metastases. Differential protein analysis was performed using two-dimensional gel electrophoresis. Candidate protein spots showing differences in expression between the two groups were identified by means of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and were validated by western blotting.

Results: We found that afamin is downregulated in the serum of papillary thyroid carcinoma patients with non-131I-avid lung metastases.

Conclusion: Afamin may be a potential serum biomarker for early screening of 131I uptake ability in DTC metastases and could therefore be of value in guiding radioiodine treatment decisions.

Show MeSH

Related in: MedlinePlus

Differentially expressed protein spots identified by 2-DE analysis in the 131I-avid group. Spots marked by circles correspond to the identified proteins listed in Table 2. Twenty-five spots that showed significant changes were selected for MALDI-TOF/TOF MS analyses. Spots 2256 and 2343 could not be picked up.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3815116&req=5

Figure 2: Differentially expressed protein spots identified by 2-DE analysis in the 131I-avid group. Spots marked by circles correspond to the identified proteins listed in Table 2. Twenty-five spots that showed significant changes were selected for MALDI-TOF/TOF MS analyses. Spots 2256 and 2343 could not be picked up.

Mentions: More than 100 protein spots were detected by 2-DE differential protein analysis. Twenty-seven differentially expressed proteins were selected on the basis of an expression difference greater than or equal to 1.5-fold between the two groups, as determined using biological variation analysis and a module of DeCyder software (GE Healthcare) (Fig. 2). However, spots 2256 and 2343 could not be picked up. Of the remaining 25 protein spots, 14 were found to be significantly upregulated and 11 were significantly downregulated in group A.


Comparative serum proteomic analysis identified afamin as a downregulated protein in papillary thyroid carcinoma patients with non-131I-avid lung metastases.

Song HJ, Xue YL, Qiu ZL, Luo QY - Nucl Med Commun (2013)

Differentially expressed protein spots identified by 2-DE analysis in the 131I-avid group. Spots marked by circles correspond to the identified proteins listed in Table 2. Twenty-five spots that showed significant changes were selected for MALDI-TOF/TOF MS analyses. Spots 2256 and 2343 could not be picked up.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3815116&req=5

Figure 2: Differentially expressed protein spots identified by 2-DE analysis in the 131I-avid group. Spots marked by circles correspond to the identified proteins listed in Table 2. Twenty-five spots that showed significant changes were selected for MALDI-TOF/TOF MS analyses. Spots 2256 and 2343 could not be picked up.
Mentions: More than 100 protein spots were detected by 2-DE differential protein analysis. Twenty-seven differentially expressed proteins were selected on the basis of an expression difference greater than or equal to 1.5-fold between the two groups, as determined using biological variation analysis and a module of DeCyder software (GE Healthcare) (Fig. 2). However, spots 2256 and 2343 could not be picked up. Of the remaining 25 protein spots, 14 were found to be significantly upregulated and 11 were significantly downregulated in group A.

Bottom Line: Differential protein analysis was performed using two-dimensional gel electrophoresis.Candidate protein spots showing differences in expression between the two groups were identified by means of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and were validated by western blotting.We found that afamin is downregulated in the serum of papillary thyroid carcinoma patients with non-131I-avid lung metastases.

View Article: PubMed Central - PubMed

Affiliation: Department of Nuclear Medicine, Shanghai Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai, China.

ABSTRACT

Background: The loss of 131I uptake ability in metastases from differentiated thyroid carcinoma (DTC) is becoming a major obstacle in radioiodine treatment. However, there is no effective way to screen for 131I uptake ability in metastases. The identification of differentially expressed proteins by serum proteomics may contribute to our understanding of the mechanisms underlying the dedifferentiation of DTC.

Materials and methods: Serum samples were obtained from papillary thyroid carcinoma patients with non-131I-avid lung metastases and 131I-avid lung metastases. Differential protein analysis was performed using two-dimensional gel electrophoresis. Candidate protein spots showing differences in expression between the two groups were identified by means of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and were validated by western blotting.

Results: We found that afamin is downregulated in the serum of papillary thyroid carcinoma patients with non-131I-avid lung metastases.

Conclusion: Afamin may be a potential serum biomarker for early screening of 131I uptake ability in DTC metastases and could therefore be of value in guiding radioiodine treatment decisions.

Show MeSH
Related in: MedlinePlus